Immutep Ltd (IMMP) News

Immutep to Participate in Upcoming Investor Conferences

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”...

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone...

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Quarterly Activities Report Q2 FY25

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in...

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients...

Patient Enrolment Completed for INSIGHT-003

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with...

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to...

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results...